

Epidemiology of Renal Cell Carcinoma

World Journal of Oncology

11, 79-87

DOI: [10.14740/wjon1279](https://doi.org/10.14740/wjon1279)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Association between copy-number alteration of +20q, 14q and 18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma. <i>Cancer Cell International</i> , 2020, 20, 482.	4.1	3
2	Renal cell carcinoma presenting as a tumor on the scalp: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 76, 56-59.	0.6	3
3	Renal Cell Tumors: Molecular Findings Reshaping Clinico-pathological Practice. <i>Archives of Medical Research</i> , 2020, 51, 799-816.	3.3	3
4	BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma. <i>Oncology</i> , 2021, 99, 240-250.	1.9	14
5	Curcumin induces apoptosis and autophagy in human renal cell carcinoma cells via Akt/mTOR suppression. <i>Bioengineered</i> , 2021, 12, 5017-5027.	3.2	18
6	An epithelial-mesenchymal transition-related long non-coding RNA signature to predict overall survival and immune microenvironment in kidney renal clear cell carcinoma. <i>Bioengineered</i> , 2021, 12, 555-564.	3.2	14
7	Comorbidity and frailty assessment in renal cell carcinoma patients. <i>World Journal of Urology</i> , 2021, 39, 2831-2841.	2.2	7
8	Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours. <i>Diagnostics</i> , 2021, 11, 272.	2.6	7
9	Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. <i>European Urology</i> , 2021, 80, 575-588.	1.9	48
10	PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 540.	1.8	47
11	Obesity-Dependent Adipokine Chemerin Suppresses Fatty Acid Oxidation to Confer Ferroptosis Resistance. <i>Cancer Discovery</i> , 2021, 11, 2072-2093.	9.4	43
12	Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma. <i>Turkish Journal of Urology</i> , 2021, 47, 113-119.	1.3	5
13	Causal Associations between Serum Urea and Cancer: A Mendelian Randomization Study. <i>Genes</i> , 2021, 12, 498.	2.4	12
14	The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 644612.	2.8	11
15	Metastatic renal cell carcinoma involving colon with unusual histologic features and diagnostic challenges: A case report. <i>International Journal of Surgery Case Reports</i> , 2021, 80, 105627.	0.6	4
16	SNHG12 promotes carcinogenesis of human renal cell cancer via functioning as a competing endogenous RNA and sponging miR-30a-3p. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4696-4708.	3.6	10
17	Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances. <i>Cancers</i> , 2021, 13, 1529.	3.7	21
18	Circular RNA ITCH Is a Tumor Suppressor in Clear Cell Renal Cell Carcinoma Metastasis through miR-106b-5p/PDCD4 Axis. <i>Journal of Immunology Research</i> , 2021, 2021, 1-10.	2.2	13

#	ARTICLE	IF	CITATIONS
19	The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments. <i>Cancers</i> , 2021, 13, 2071.	3.7	25
20	Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. <i>Current Oncology</i> , 2021, 28, 1402-1411.	2.2	11
21	Molecular Boronic Acid-Based Saccharide Sensors. <i>ACS Sensors</i> , 2021, 6, 1508-1528.	7.8	83
22	Dysregulation of miR-638 in the progression of cancers. <i>Pathology Research and Practice</i> , 2021, 220, 153351.	2.3	7
23	Endogenous Retroviral ω K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 657187.	2.8	16
24	Renal Cell Carcinoma Metastasis to the Breast: A Rare Presentation. <i>Case Reports in Radiology</i> , 2021, 2021, 1-9.	0.3	2
25	PAPP ω A functions as a tumor suppressor and is downregulated in renal cell carcinoma. <i>FEBS Open Bio</i> , 2021, 11, 1593-1606.	2.3	3
26	Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 634830.	2.8	10
27	Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 2511-2521.	1.1	1
28	The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 10926.	3.3	7
29	Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 701345.	2.8	4
30	Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. <i>PLoS ONE</i> , 2021, 16, e0253236.	2.5	13
31	Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.01082.	2.9	6
33	Metachronous Renal Cell Carcinoma: A Rare Presentation of Adrenal Crisis. <i>Cureus</i> , 2021, 13, e15965.	0.5	0
34	Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 1057-1069.	1.6	6
35	Circulating Levels of the Interferon- γ -Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. <i>Cancers</i> , 2021, 13, 2849.	3.7	10
36	Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. <i>Cancers</i> , 2021, 13, 3016.	3.7	38
37	Synthetic data in machine learning for medicine and healthcare. <i>Nature Biomedical Engineering</i> , 2021, 5, 493-497.	22.5	249

#	ARTICLE	IF	CITATIONS
38	RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. <i>Advanced Science</i> , 2021, 8, e2100881.	11.2	54
39	Expression of AOX1 Predicts Prognosis of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 683173.	2.3	5
40	Identification of miR-20a-5p as Robust Normalizer for Urine microRNA Studies in Renal Cell Carcinoma and a Profile of Dysregulated microRNAs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7913.	4.1	8
41	Integration of NRP1, RGS5 and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 590-603.	3.0	6
42	Prevalence of Renal Cell Carcinoma in Samples Sent to the Pathology Department of Kabul University of Medical Sciences and City Medical Laboratory. <i>International Journal of Cancer Management</i> , 2021, 14, .	0.4	0
43	Laparoscopic single port radical nephrectomy challenges: a case presentation. <i>Onkourologiya</i> , 2021, 17, 168-171.	0.3	0
44	Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6930.	2.5	4
45	Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC. <i>Cancers</i> , 2021, 13, 4140.	3.7	14
46	Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma. <i>Future Oncology</i> , 2021, 17, 3051-3060.	2.4	3
47	Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer. <i>Cancers</i> , 2021, 13, 4213.	3.7	15
48	Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line. <i>Targeted Oncology</i> , 2021, 16, 643-652.	3.6	7
49	Identification of a glycolysis-related lncRNA prognostic signature for clear cell renal cell carcinoma. <i>Bioscience Reports</i> , 2021, 41, .	2.4	8
50	Chromophobe renal cell carcinoma: A case report and literature review. <i>Annals of Medicine and Surgery</i> , 2021, 68, 102643.	1.1	0
51	Determining the immunohistochemical expression of GLUT1 in renal cell carcinoma using the HSCORE method. <i>Biomedical Reports</i> , 2021, 15, 79.	2.0	4
52	Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. <i>Frontiers in Oncology</i> , 2021, 11, 707214.	2.8	26
53	Research highlights of the 2020 society of urologic oncology young urologic oncologists™ program. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 452-454.	1.6	0
54	Late metastatic recurrence of renal cell carcinoma in the heart and mediastinum: A case report and review of literature. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100119.	0.1	1
55	Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes. <i>Journal of Personalized Medicine</i> , 2021, 11, 996.	2.5	20

#	ARTICLE	IF	CITATIONS
56	Downregulation of PPA2 expression correlates with poor prognosis of kidney renal clear cell carcinoma. PeerJ, 2021, 9, e12086.	2.0	2
57	The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database. Scientific Reports, 2021, 11, 17822.	3.3	20
58	Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 837.e1-837.e7.	1.6	2
59	BAI1 as a Prognostic Marker of Clear Cell Renal Cell Carcinoma (ccRCC). Anticancer Research, 2021, 41, 4463-4470.	1.1	0
60	Renal Lipid Metabolism Abnormalities in Obesity and Clear Cell Renal Cell Carcinoma. Metabolites, 2021, 11, 608.	2.9	13
61	The Clinical Relevance and Tumor Promoting Function of C19orf10 in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 2021, 11, 725959.	2.8	3
62	Impact of Histology and Tumor Grade on Clinical Outcomes Beyond 5 Years of Follow-Up in a Large Cohort of Renal Cell Carcinomas. Clinical Genitourinary Cancer, 2021, 19, e280-e285.	1.9	2
63	Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review. Journal of Cancer Survivorship, 2022, 16, 1279-1295.	2.9	10
64	Acute renal failure in patient with renal cell carcinoma after combination immune checkpoint inhibitor therapy. Current Problems in Cancer Case Reports, 2021, 4, 100082.	0.1	0
65	Diagnosis of bone metastases in urological malignanciesâ€”an update. , 2022, , 827-849.		0
66	Daily online adaptive magnetic resonance image (MRI) guided stereotactic body radiation therapy for primary renal cell cancer. Medical Dosimetry, 2021, 46, 289-294.	0.9	6
67	Downregulation of enhancer RNA EMX2OS is associated with poor prognosis in kidney renal clear cell carcinoma. Aging, 2020, 12, 25865-25877.	3.1	20
68	Endoscopic nephrectomy and kidney resection in children with renal cell carcinoma. Description of clinical cases and literature review. Russian Journal of Pediatric Hematology and Oncology, 2021, 8, 109-115.	0.3	0
69	Clinical Significance of ADAMTS19, BMP7, SIM1, and SFRP1 Promoter Methylation in Renal Clear Cell Carcinoma. OncoTargets and Therapy, 2021, Volume 14, 4979-4990.	2.0	2
70	MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma. Cancer Management and Research, 2021, Volume 13, 7663-7675.	1.9	16
71	Self-reported quality of life as a predictor of mortality in renal cell carcinoma. Cancer, 2022, 128, 479-486.	4.1	3
72	Intractable Cough Associated With Renal Cell Carcinoma. Cureus, 2021, 13, e18727.	0.5	0
73	Metastatic Clear Cell Renal Cell Carcinoma: The Great Pretender and the Great Dilemma. World Journal of Oncology, 2021, 12, 178-182.	1.5	5

#	ARTICLE	IF	CITATIONS
74	Loss of DUSP4 Expression as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma. <i>Diagnostics</i> , 2021, 11, 1939.	2.6	3
75	Metastasectomy in kidney cancer: current indications and treatment approaches. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 266-275.	1.3	4
76	Modified calcium from waste by product of crustaceans (polymesoda erosa)shell as alternative sunscreen materials. <i>Journal of Analytical & Pharmaceutical Research</i> , 2019, 8, 180-183.	1.0	1
77	Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma. , 2021, 7, .		16
78	Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 746976.	2.8	21
79	Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas. <i>Urology</i> , 2022, 160, 87-93.	1.0	7
80	Circular RNAs in renal cell carcinoma: Functions in tumorigenesis and diagnostic and prognostic potentials. <i>Pathology Research and Practice</i> , 2022, 229, 153720.	2.3	20
81	Sensitization Effects of Repurposed Blood Pressure-regulating Drugs on Drug-resistant Cancer Cells. <i>Anticancer Research</i> , 2021, 41, 6179-6190.	1.1	5
82	A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 6199-6209.	1.1	7
83	Immunization with short peptide particles reveals a functional CD8 ⁺ T-cell neoepitope in a murine renal carcinoma model. , 2021, 9, e003101.		7
84	Upregulation of TMEM45A Promoted the Progression of Clear Cell Renal Cell Carcinoma in vitro. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6421-6430.	3.5	3
85	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. <i>ESMO Open</i> , 2021, 6, 100304.	4.5	14
86	Epigenetic inactivation of ACAT1 promotes epithelial-mesenchymal transition of clear cell renal cell carcinoma. <i>Genes and Genomics</i> , 2022, , 1.	1.4	2
88	Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. <i>Journal of Geriatric Oncology</i> , 2022, 13, 635-643.	1.0	1
89	First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape. <i>Oncologist</i> , 2022, 27, 125-134.	3.7	9
90	Developing Bayesian Networks based Prognostic Radiomics Model for Clear Cell Renal Cell Carcinoma Patients. , 2020, , .		0
91	Urine-Based Metabolomics and Machine Learning Reveals Metabolites Associated with Renal Cell Carcinoma Stage. <i>Cancers</i> , 2021, 13, 6253.	3.7	10
92	Identification of a Hypoxia-Related Gene Model for Predicting the Prognosis and Formulating the Treatment Strategies in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 806264.	2.8	8

#	ARTICLE	IF	CITATIONS
93	Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 81, 349-361.	1.9	61
94	Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1a: a systematic review. <i>Systematic Reviews</i> , 2022, 11, 4.	5.3	5
95	Assessing Depressive Symptoms in Patients With Cancer Treated With Interleukin-2. <i>Cancer Nursing</i> , 2022, Publish Ahead of Print, .	1.5	0
96	The Value of Metastasectomy in Renal Cell Carcinoma in 2021. <i>Indian Journal of Surgery</i> , 0, , 1.	0.3	0
97	Case of the month from the Department of Urology, Oxford University Hospitals, Oxford, UK: open partial nephrectomy of a transplant kidney in a patient with Fabry's disease. <i>BJU International</i> , 2022, 129, 164-167.	2.5	0
99	A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 2072-2084.	3.8	0
100	Potential Use of CTCs as Biomarkers in Renal Cancer Patients. <i>Life</i> , 2022, 12, 89.	2.4	6
101	Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 814228.	2.8	7
102	Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?. <i>Advances in Therapy</i> , 2022, 39, 1107-1125.	2.9	10
103	Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients. <i>Diagnostics</i> , 2022, 12, 336.	2.6	5
105	Preoperative stereotactic body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumour thrombus: study protocol for a single-arm cohort trial. <i>BMJ Open</i> , 2022, 12, e055364.	1.9	3
106	Angioprevention of Urologic Cancers by Plant-Derived Foods. <i>Pharmaceutics</i> , 2022, 14, 256.	4.5	11
108	Masseter Muscle Metastasis of Renal Cell Carcinoma: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, 830195.	2.8	1
109	A case report of the world largest spindle cell renal tumor (9 kg) with longest survival, removed by innovative technique. <i>Urology Case Reports</i> , 2022, 42, 102011.	0.3	0
110	Overexpression of Parkin in clear cell renal cell carcinoma decreases tumor aggressiveness by regulating CKS2 levels. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	2
111	Comprehensive analysis of PTEN-related ceRNA network revealing the key pathways WDFY3-AS2-miR-21-5p/miR-221-3p/miR-222-3p-TIMP3 as potential biomarker in tumorigenesis and prognosis of kidney renal clear cell carcinoma. <i>Molecular Carcinogenesis</i> , 2022, 61, 508-523.		7
112	Association between C-reactive protein and risk of overall and 18 site-specific cancers in a Japanese case-cohort. <i>British Journal of Cancer</i> , 2022, 126, 1481-1489.	6.4	9
113	Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 711142.	2.3	0

#	ARTICLE	IF	CITATIONS
114	Downregulation of lncRNA APCDD1L-AS1 due to DNA hypermethylation and loss of VHL protein expression promotes the progression of clear cell renal cell carcinoma. <i>International Journal of Biological Sciences</i> , 2022, 18, 2583-2596.	6.4	6
115	OUP accepted manuscript. <i>International Journal of Epidemiology</i> , 2022, , .	1.9	1
116	A potential impact of A Disintegrin and Metalloproteinase DomainLike Protein Decysin-1 (ADAMDEC1) on clear cell renal cell carcinoma propagation. <i>Biocell</i> , 2022, 46, 1-9.	0.7	1
117	Mixup Augmentation for Kidney and Kidney Tumor Segmentation. <i>Lecture Notes in Computer Science</i> , 2022, , 90-97.	1.3	5
118	Impacts of Neighborhood Characteristics and Surgical Treatment Disparities on Overall Mortality in Stage I Renal Cell Carcinoma Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2050.	2.6	2
119	Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1299-1311.	2.5	23
120	DLEU7-AS1 promotes renal cell cancer by silencing the miR-26a-5p/coronin-3 axis. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.9	1
121	Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers. <i>Pharmaceuticals</i> , 2022, 15, 295.	3.8	7
122	The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2022, 34, 234-242.	2.4	16
123	Exposureâ€“response analyses of cabozantinib in patients with metastatic renal cell cancer. <i>BMC Cancer</i> , 2022, 22, 228.	2.6	11
124	Socioâ€“economic burden of disease: Survivorship costs for renal cell carcinoma. <i>European Journal of Cancer Care</i> , 2022, 31, .	1.5	1
125	Mapping the human kidney using single-cell genomics. <i>Nature Reviews Nephrology</i> , 2022, 18, 347-360.	9.6	34
126	Expression levels of sonic hedgehog pathway genes and their targets are upregulated in early clear cell renal cell carcinoma. <i>International Journal of Molecular Medicine</i> , 2022, 49, .	4.0	13
127	Safety, efficacy, and mid-term oncological outcomes of computed tomography-guided cryoablation of T1 renal cancer. <i>Acta Radiologica</i> , 2022, , 028418512210818.	1.1	3
128	Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2073-2084.	4.1	6
129	miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2022, 12, 3537.	3.3	4
130	A Simple-To-Use Nomogram for Predicting Early Death in Metastatic Renal Cell Carcinoma: A Population-Based Study. <i>Frontiers in Surgery</i> , 2022, 9, 871577.	1.4	3
131	Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands. <i>Frontiers in Pharmacology</i> , 2022, 13, 803935.	3.5	8

#	ARTICLE	IF	CITATIONS
132	Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics. <i>Frontiers in Oncology</i> , 2022, 12, 871252.	2.8	8
133	Preoperative Embolization of a Delayed Femoral Metastasis of Renal Cell Carcinoma: A Case Report. <i>Cureus</i> , 2022, 14, e23788.	0.5	0
134	Pharmacokinetics and Bioequivalence of a Generic and a Branded Pazopanib Tablet in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2022, , .	1.6	0
135	Origins and Timing of Emerging Lesions in Advanced Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2022, 20, 909-922.	3.4	0
136	Renal cell carcinoma uvula metastasis leading to airway compromise: an unusual site. <i>BMJ Case Reports</i> , 2022, 15, e248098.	0.5	0
137	Renal cancer: First look at a potential South African urological cancer registry. , 2021, 1, 25-28.		0
138	Percutaneous ablation of renal tumors versus surgical ablation and partial nephrectomy: Medicare trends and reimbursement cost comparison from 2010 to 2018. <i>Abdominal Radiology</i> , 2022, 47, 885-890.	2.1	1
139	Renal cancer: First look at a potential South African urological cancer registry. , 2021, 1, 25-28.		0
140	Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 735803.	2.8	21
141	Association between Human Papillomavirus and Urological Cancers: An Update. , 0, , .		1
142	Clampless Laparoscopic Tumor Enucleation for Exophytic Masses Greater Than 4â€‰cm: Is Renorrhaphy Necessary?. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2022, 32, 931-937.	1.0	2
143	Evaluating Established Roles, Future Perspectives and Methodological Heterogeneity for Wilmsâ€™ Tumor 1 (WT1) Antigen Detection in Adult Renal Cell Carcinoma, Using a Novel N-Terminus Targeted Antibody (Clone WT49). <i>Biomedicines</i> , 2022, 10, 912.	3.2	5
144	N7-Methylguanosine-Related lncRNAs: Integrated Analysis Associated With Prognosis and Progression in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 871899.	2.3	16
145	The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 790381.	2.8	5
146	Resource Use in Advanced Renal Cancer with the Payer Institution Perspective: The Case of Training and Research Hospital. <i>SÃ¼leyman Demirel Ãœniversitesi Vizyoner Dergisi</i> , 2022, 13, 520-534.	0.6	1
147	Transient Receptor Potential Channel 1 Potentially Serves as a Biomarker Indicating T/TNM Stages and Predicting Long-Term Prognosis in Patients With Renal Cell Carcinoma. <i>Frontiers in Surgery</i> , 2022, 9, 853310.	1.4	3
148	Using a small dataset to classify strength-interactions with an elastic display: a case study for the screening of autism spectrum disorder. <i>International Journal of Machine Learning and Cybernetics</i> , 2023, 14, 151-169.	3.6	3
149	Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 565-574.	2.4	1

#	ARTICLE	IF	CITATIONS
150	Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e396-e405.	1.9	1
151	A Novel Machine Learning 13-Gene Signature: Improving Risk Analysis and Survival Prediction for Clear Cell Renal Cell Carcinoma Patients. <i>Cancers</i> , 2022, 14, 2111.	3.7	12
152	Extracellular Vesiclesâ€”A New Potential Player in the Immunology of Renal Cell Carcinoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 772.	2.5	1
153	Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 2330-2343.	2.6	0
154	RNA Sequencing Reveals Alterations and Similarities in Cell Metabolism, Hypoxia and Immune Evasion in Primary Cell Cultures of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	0
155	Contrast-Enhanced Ultrasound (CEUS) in the Evaluation of Renal Masses with Histopathological Validationâ€”Results from a Prospective Single-Center Study. <i>Diagnostics</i> , 2022, 12, 1209.	2.6	12
156	Renal cell carcinoma with inferior vena cava tumor thrombus initially misdiagnosed as bland thrombus due to hypercoagulable state. <i>SAGE Open Medical Case Reports</i> , 2022, 10, 2050313X2211020.	0.3	0
158	Renal peritumoral adipose tissue undergoes a browning process and stimulates the expression of epithelial-mesenchymal transition markers in human renal cells. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
159	Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 115-122.	0.1	0
160	Applied Change Management in Interventional Radiologyâ€”Implementation of Percutaneous Thermal Ablation as an Additional Therapeutic Method for Small Renal Masses. <i>Diagnostics</i> , 2022, 12, 1301.	2.6	0
161	Epidemiological and Histopathological Characteristics of Renal Cell Carcinoma in Somalia. <i>Cancer Management and Research</i> , 0, Volume 14, 1837-1844.	1.9	0
162	MicroRNA-4735-3p Facilitates Ferroptosis in Clear Cell Renal Cell Carcinoma by Targeting SLC40A1. <i>Analytical Cellular Pathology</i> , 2022, 2022, 1-12.	1.4	16
163	KMT2B promotes the growth of renal cell carcinoma via upregulation of SNHG12 expression and promotion of CEP55 transcription. <i>Cancer Cell International</i> , 2022, 22, .	4.1	4
164	Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009â€”2018. , 2022, 152, .		0
165	Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature. <i>Journal of Kidney Cancer and VHL</i> , 2022, 9, 32-38.	1.0	2
166	New imaging technologies for robotic kidney cancer surgery. <i>Asian Journal of Urology</i> , 2022, 9, 253-262.	1.2	14
167	An update on the current epidemiological status of metastatic neoplasms to the thyroid. <i>Cancer Epidemiology</i> , 2022, 79, 102192.	1.9	1
168	Tanshinone IIA exerts autophagic cell death through down-regulation of β -catenin in renal cell carcinoma cells. <i>Biochimie</i> , 2022, 200, 119-130.	2.6	9

#	ARTICLE	IF	CITATIONS
170	Ocular adnexal metastases from renal cell carcinoma: An update and comprehensive literature review. <i>Saudi Journal of Ophthalmology</i> , 2021, 35, 209.	0.3	1
171	Heterogeneity of Platelet Derived Growth Factor Pathway Gene Expression Profile Defines Three Distinct Subgroups of Renal Cell Carcinomas. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 477-489.	2.0	7
172	Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient. <i>Bulletin Du Cancer</i> , 2022, 109, 2S4-2S18.	1.6	3
173	Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103750.	4.4	8
174	Papillary renal cell carcinoma: current and controversial issues. <i>Current Opinion in Urology</i> , 2022, 32, 344-351.	1.8	11
175	Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. <i>Clinical Drug Investigation</i> , 0, , .	2.2	0
176	Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study. <i>BMC Cancer</i> , 2022, 22, .	2.6	0
177	Integrated bioinformatics analysis to identify the key gene associated with metastatic clear cell renal cell carcinoma. , 2022, 39, .		1
178	Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	5
179	Reduced number of IFN γ producing cells in peripheral blood is a biomarker for patients with renal cell carcinoma. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	2.7	0
180	Adjuvant therapy in renal cell carcinoma: Ready, steady, should we go?. <i>Bulletin Du Cancer</i> , 2022, , .	1.6	0
181	Muscle mass change using linear measurement analysis after nephrectomy for pT3 and pT4 renal cell carcinoma is associated with mortality. <i>JCSM Rapid Communications</i> , 2022, 5, 205-211.	1.6	2
182	Metastasis to the Bladder: A Rare Site of Recurrence of Renal Cell Carcinoma. <i>Case Reports in Urology</i> , 2022, 2022, 1-5.	0.3	0
183	Artificial intelligence for renal cancer: From imaging to histology and beyond. <i>Asian Journal of Urology</i> , 2022, 9, 243-252.	1.2	10
184	Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	5
185	Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211086.	3.2	15
186	Macrophage Phenotype in Combination with Tumor Microbiome Composition Predicts RCC Patients'™ Survival: A Pilot Study. <i>Biomedicines</i> , 2022, 10, 1516.	3.2	4
187	Renal Cell Carcinoma: A Complex Therapeutic Challenge in the Elderly. <i>Cureus</i> , 2022, , .	0.5	3

#	ARTICLE	IF	CITATIONS
188	Nomogram predictive model for differentiation between renal oncocytoma and chromophobe renal cell carcinoma at multi-phasic CT: a retrospective study. <i>Clinical Radiology</i> , 2022, , .	1.1	0
189	Chronic abdominal pain and Budd-Chiari Syndrome: A relentless quest for an underlying neoplastic etiology. <i>Canadian Liver Journal</i> , 0, , .	0.9	0
190	Characteristics of Gut Microbiota in Patients With Clear Cell Renal Cell Carcinoma. <i>Frontiers in Microbiology</i> , 0, 13, .	3.5	9
191	Complete Resolution of Right Atrium Tumor Thrombus with Immunotherapy: A Case Report. <i>Current Problems in Cancer Case Reports</i> , 2022, , 100180.	0.1	0
192	The Current Status of Kidney Cancer Urine Markers – A systematic review. <i>Kidney Cancer</i> , 2022, , 1-6.	0.4	0
193	Clinical and oncological outcomes of open partial nephrectomy versus robot assisted partial nephrectomy over 15 years. <i>Journal of Robotic Surgery</i> , 2023, 17, 519-526.	1.8	4
194	Simultaneous robot-assisted approach in a super-elderly patient with urothelial carcinoma and synchronous contralateral renal cell carcinoma: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 7153-7162.	0.8	1
195	Partial nephrectomy versus percutaneous cryoablation of small renal cell carcinomas – A comparison of complications in a prospective multicenter cohort study. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.5	2
196	Comparative Analysis for the Distinction of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma in Computed Tomography Imaging Using Machine Learning Radiomics Analysis. <i>Cancers</i> , 2022, 14, 3609.	3.7	5
197	Diagnostic Strategies for Urologic Cancer Using Expression Analysis of Various Oncogenic Surveillance Molecules – From Non-Coding Small RNAs to Cancer-Specific Proteins. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 7390.	2.5	0
198	A Four-MicroRNA Panel in Serum as a Potential Biomarker for Screening Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	3
199	Pancreatectomy for metastatic renal cell carcinoma: twenty years of experience at a tertiary centre. <i>International Surgery Journal</i> , 2022, 9, 1460.	0.1	0
200	Analysis and Prediction of the Survival Trends of Patients with Clear-Cell Renal Cell Carcinoma: A Model-Based Period Analysis, 2001-2015. <i>Cancer Control</i> , 2022, 29, 107327482211212.	1.8	1
201	Clinical implications of epigenetics in Renal Cell Carcinoma. <i>Archives of Renal Diseases and Management</i> , 2022, 7, 008-013.	0.3	0
202	Overexpressed lncRNA FTX promotes the cell viability, proliferation, migration and invasion of renal cell carcinoma via FTX/miR-4429/UBE2C axis. <i>Oncology Reports</i> , 2022, 48, .	2.6	10
203	Robot-assisted partial nephrectomy with calicolithotomy. <i>Urologicheskie Vedomosti</i> , 2022, 12, 167-173.	0.3	0
204	Multiple Cancer Combating by Natural Bioactives: A Review. <i>Current Cancer Therapy Reviews</i> , 2022, 18, .	0.3	0
205	Interleukin 17 and Its Involvement in Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 4973.	2.4	3

#	ARTICLE	IF	CITATIONS
206	Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. <i>Cells</i> , 2022, 11, 2505.	4.1	3
207	Epidemiology and Prevention of Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4059.	3.7	31
208	A multiomics disease progression signature of low-risk ccRCC. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
209	Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy. <i>Medicine (United States)</i> , 2022, 101, e29510.	1.0	0
210	Buccal Mucosal Metastasis of Renal Cell Carcinoma: A Case Report and Review of Literature. <i>International Journal of Clinical Research</i> , 2022, 3, 132-137.	0.0	0
211	Diagnostic Accuracy of <scp>MRI</scp> for Solid Renal Masses: A Systematic Review and Meta-analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 1172-1184.	3.4	2
212	Effect of AKT silence on malignant biological behavior of renal cell carcinoma cells. <i>BMC Urology</i> , 2022, 22, .	1.4	0
213	Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function Outcomes. <i>Clinical Oncology</i> , 2023, 35, 20-28.	1.4	5
214	Prognostic Gene Expression-Based Signature in Clear-Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 3754.	3.7	10
215	Tumor-associated macrophages promote migration and invasion via modulating IL-6/STAT3 signaling in renal cell carcinoma. <i>International Immunopharmacology</i> , 2022, 111, 109139.	3.8	7
216	The application of 3D bioprinting in urological diseases. <i>Materials Today Bio</i> , 2022, 16, 100388.	5.5	17
217	Role of axitinib and other tyrosine kinase inhibitors in the management of metastatic renal cell carcinoma. <i>Journal of Current Oncology</i> , 2022, 5, 35.	0.2	0
218	Renal Cell Carcinoma with Supradiaphragmatic Tumor Thrombus: Avoiding Sternotomy and Cardiopulmonary Bypass. <i>Medical Research Archives</i> , 2022, 10, .	0.2	4
219	Treatment of Patients and Mechanisms of Development of Combined of Urolithiasis and Kidney Tumors (Literature review). <i>Health of Man</i> , 2022, , 80-85.	0.0	0
220	MANAGEMENT OF HAEMATURIA IN A TERTIARY HEALTH INSTITUTION IN NIGERIA. <i>International Journal of Health Sciences</i> , 2022, 5, 16-29.	0.0	0
221	Correlation between Genes of the ceRNA Network and Tumor-Infiltrating Immune Cells and Their Biomarker Screening in Kidney Renal Clear Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	1.3	1
222	Family History of Cancers Increases Risk of Renal Cell Carcinoma in a Chinese Population. <i>Cancer Management and Research</i> , 0, Volume 14, 2561-2568.	1.9	0
223	Glycosylation in Renal Cell Carcinoma: Mechanisms and Clinical Implications. <i>Cells</i> , 2022, 11, 2598.	4.1	4

#	ARTICLE	IF	CITATIONS
224	Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9898.	4.1	2
225	Compound C Inhibits Renca Renal Epithelial Carcinoma Growth in Syngeneic Mouse Models by Blocking Cell Cycle Progression, Adhesion and Invasion. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9675.	4.1	1
226	Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG/EGFR signaling in renal cell carcinoma. <i>Molecular Cancer</i> , 2022, 21, .	19.2	15
227	Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
228	Role of cytoreductive surgery in the era of immunotherapy. <i>Current Opinion in Urology</i> , 2022, 32, 618-626.	1.8	5
229	CD47 Expression Predicts Unfavorable Prognosis in Clear Cell Renal Cell Carcinoma after Curative Resection. <i>Diagnostics</i> , 2022, 12, 2291.	2.6	2
230	A cuproptosis-related lncRNA signature identified prognosis and tumour immune microenvironment in kidney renal clear cell carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	4
231	Clear Cell Renal Cancer, a Tumour with Neuroendocrine Features Originating from the Erythropoietin-Producing Cell. , 0, , .		2
232	Altered Plasma, Urine, and Tissue Profiles of Sulfatides and Sphingomyelins in Patients with Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4622.	3.7	6
233	In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10177.	4.1	3
234	STAT3 and Its Pathwaysâ€™ Dysregulationâ€™ Underestimated Role in Urological Tumors. <i>Cells</i> , 2022, 11, 3024.	4.1	8
235	Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4607.	3.7	2
236	Elevated Plasma Interleukin-35 as a Prognostic Indicator in Localized Clear Cell Renal Cell Carcinoma. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-9.	1.2	1
237	Organic Anion Transporters (OAT) and Other SLC22 Transporters in Progression of Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4772.	3.7	4
238	Tumoral Overexpression of Hepcidin is Associated with Poor Prognosis of Patients with Clear Cell Renal Cell Carcinoma. <i>Cancer Investigation</i> , 2023, 41, 84-92.	1.3	1
239	Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer. , 2022, , 201-231.		0
240	Aberrant expression of poloâ€™like kinase 4 in renal cell carcinoma: Association with clinicopathological characteristics and longâ€™term survival. <i>Oncology Letters</i> , 2022, 24, .	1.8	2
241	CBX Family Members in Two Major Subtypes of Renal Cell Carcinoma: A Comparative Bioinformatic Analysis. <i>Diagnostics</i> , 2022, 12, 2452.	2.6	3

#	ARTICLE	IF	CITATIONS
243	Editorial: Influences in the progression of renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
244	The Dimensions of Reports From Around the World That Address Diversity in Oncology. <i>World Journal of Oncology</i> , 2022, 13, 241-243.	1.5	1
245	Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease—Results of a Prospective Trial. <i>Cancers</i> , 2022, 14, 5069.	3.7	7
247	Impact of Partial Nephrectomy and Percutaneous Cryoablation on Short-term Health-related Quality of Life—A Prospective Comparative Cohort Study. <i>European Urology Open Science</i> , 2022, 45, 99-107.	0.4	2
248	Use of High-Plex Data Reveals Novel Insights into the Tumour Microenvironment of Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 5387.	3.7	1
249	Epigenetics in advanced renal cell carcinoma: Potential new targets. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103857.	4.4	2
250	Ultrasound findings of subcutaneous soft tissue metastasis of renal cell carcinoma: A case report. <i>Radiology Case Reports</i> , 2023, 18, 192-195.	0.6	1
251	The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape. <i>Cancers</i> , 2022, 14, 5486.	3.7	1
252	Texture and CT-features in differentiation of hypervascular pancreatic neuroendocrine tumors from renal cell carcinoma metastases: diagnostic model. <i>Medical Visualization</i> , 0, , .	0.4	0
253	Clinicopathologic features of renal cell carcinomas seen at the Aga Khan University Hospital in Kenya. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	0
254	Association between decreased ipsilateral renal function and aggressive behavior in renal cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	2.6	0
255	Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
256	Stereotactic Body Radiotherapy for Localized Kidney Cancer. <i>Current Urology Reports</i> , 2022, 23, 371-381.	2.2	3
258	Cryoablation for the Treatment of Kidney Cancer: Comparison With Other Treatment Modalities and Review of Current Treatment. <i>Cureus</i> , 2022, , .	0.5	0
259	Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma. <i>JACC: CardioOncology</i> , 2022, 4, 522-531.	4.0	12
260	Sustained release system of paclitaxel based on composite nanofibers for inhibiting renal clear cell carcinoma. <i>Journal of Materials Science</i> , 0, , .	3.7	0
261	Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma. <i>Biomedicines</i> , 2022, 10, 2953.	3.2	10
262	Crisis Averted: Clinical T1b Renal Mass with Concurrent Arteriovenous Malformation and Renal Vein Thrombus. <i>Case Reports in Urology</i> , 2022, 2022, 1-5.	0.3	0

#	ARTICLE	IF	CITATIONS
263	Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential <i>VHL</i> Mutations Underlie Multifocal ccRCC. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 740-746.	2.0	2
264	STEAP3 can predict the prognosis and shape the tumor microenvironment of clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	2.6	3
266	Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy. <i>Cancer Research and Treatment</i> , 2023, 55, 643-651.	3.0	1
267	Evaluation of 5 Fraction Stereotactic Body Radiation Therapy (SBRT) for Osseous Renal Cell Carcinoma Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 501-505.	1.3	2
268	TOLLIP Protein Expression Predicts Unfavorable Outcome in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14702.	4.1	3
269	Renal cell carcinoma - epidemiology, risk factors, diagnosis and treatment - review article. <i>Journal of Education, Health and Sport</i> , 2022, 13, 275-280.	0.1	0
270	Renal cell carcinoma: the population, real world, and cost-of-illness. <i>BMC Urology</i> , 2022, 22, .	1.4	0
271	Age-Related Differences in Oncological Outcomes in Renal Cell Carcinoma: Impact of Functional Conservation as Measured by Postoperative eGFR. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e219-e227.	1.9	0
272	Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e166-e174.	1.9	0
273	A Rare Case of Renal Cell Carcinoma With Inferior Vena Cava Invasion: A Life-Threatening Complication. <i>Cureus</i> , 2022, , .	0.5	0
274	Comparative G-Protein-Coupled Estrogen Receptor (GPER) Systems in Diabetic and Cancer Conditions: A Review. <i>Molecules</i> , 2022, 27, 8943.	3.8	4
275	Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. <i>Biomedicines</i> , 2022, 10, 3172.	3.2	2
276	High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 5985.	3.7	8
277	Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the <i>CLEAR</i> study. <i>Cancer Medicine</i> , 2023, 12, 6902-6912.	2.8	3
278	Types of Cancer and Research Covered in <i>World Journal of Oncology</i> . <i>World Journal of Oncology</i> , 2022, 13, 325-328.	1.5	0
279	Manipulation of Amino Acid Levels with Artificial Diets Induces a Marked Anticancer Activity in Mice with Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16132.	4.1	2
280	CD70-Targeted Micelles Enhance HIF2 α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells. <i>Molecules</i> , 2022, 27, 8457.	3.8	4
281	A Brief Review of Artificial Intelligence in Genitourinary Oncological Imaging. <i>Canadian Association of Radiologists Journal</i> , 2023, 74, 534-547.	2.0	3

#	ARTICLE	IF	CITATIONS
282	A developed ant colony algorithm for cancer molecular subtype classification to reveal the predictive biomarker in the renal cell carcinoma. <i>Biocell</i> , 2023, 47, 555-567.	0.7	0
283	Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma. <i>Biomedicines</i> , 2023, 11, 181.	3.2	4
284	Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature. <i>Current Oncology</i> , 2023, 30, 923-937.	2.2	5
285	The expression and significance of long non-coding RNA ITGB2-AS1 in renal clear cell carcinoma. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2023, 44, 19-28.	1.1	0
286	Pre-treatment systemic immune-inflammation index as a non-invasive biomarker for predicting clinical outcomes in patients with renal cell carcinoma: a meta-analysis of 20 studies. <i>Biomarkers</i> , 2023, 28, 249-262.	1.9	1
287	Inhibition of Cyclin F Promotes Cellular Senescence through Cyclin-dependent Kinase 1-mediated Cell Cycle Regulation. <i>Current Medical Science</i> , 2023, 43, 246-254.	1.8	1
288	The Role of Immunotherapy in Renal Cell Carcinoma. , 2023, , 1-31.		0
289	<i>Euphorbia neriifolia</i> (Indian Spurge Tree): A Plant of Multiple Biological and Pharmacological Activities. <i>Sustainability</i> , 2023, 15, 1225.	3.2	7
290	Effect of Bisphosphonates on Skeletal Related Events in Long Bone Metastases of Renal Cell Carcinoma: A Systematic Review. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e190-e197.	1.9	1
291	The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
292	Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?. <i>Journal of Cancer Research and Therapeutics</i> , 2023, .	0.9	2
293	Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2023, 28, 416-426.	2.2	1
294	Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1633-1646.	4.2	4
295	The Role of miRNA in the Management of Localized and Advanced Renal Masses, a Narrative Review of the Literature. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 275.	2.5	5
296	Circulating Tumor Cells as Biomarkers for Renal Cell Carcinoma: Ready for Prime Time?. <i>Cancers</i> , 2023, 15, 287.	3.7	4
297	A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan. <i>International Journal of Urology</i> , 2023, 30, 723-729.	1.0	2
299	Patient Factors Impacting Perioperative Outcomes for T1b-T2 Localized Renal Cell Carcinoma May Guide Decision for Partial versus Radical Nephrectomy. <i>Journal of Clinical Medicine</i> , 2023, 12, 175.	2.4	1
300	Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. <i>Oncologist</i> , 2023, 28, 333-340.	3.7	1

#	ARTICLE	IF	CITATIONS
301	Computational Gene Expression and Network Analysis of Myc Reveal Insights into Its Diagnostic and Prognostic Role in Subtypes of Renal Cancer. <i>Applied Biochemistry and Biotechnology</i> , 2023, 195, 4251-4276.	2.9	5
302	Clear Cell Renal Cell Carcinoma: From Biology to Treatment. <i>Cancers</i> , 2023, 15, 665.	3.7	11
303	The Variations [™] in Genes Encoding TIM-3 and Its Ligand, Galectin-9, Influence on ccRCC Risk and Prognosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2042.	4.1	2
304	The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	0
306	The Changing Epidemiology of Adrenal Insufficiency: Iatrogenic Factors Predominate. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.2	7
307	Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. <i>European Urology Oncology</i> , 2023, 6, 437-446.	5.4	4
308	The role of cytoreductive nephrectomy in the immuno-oncological therapy era. <i>Current Opinion in Urology</i> , 0, Publish Ahead of Print, .	1.8	1
309	Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients [™] Outcomes?. <i>Cancers</i> , 2023, 15, 793.	3.7	6
310	The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug [™] Drug Interactions of Tyrosine Kinase Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2101.	4.1	2
311	HSP70 Expression Signature in Renal Cell Carcinoma: A Clinical and Bioinformatic Analysis Approach. <i>Genes</i> , 2023, 14, 355.	2.4	1
312	Expression of PD-L1 in renal cancer, prognostic features and clinical utility of its routine staining. <i>Actas Urol³gicas Espa[±]olas (English Edition)</i> , 2023, 47, 271-278.	0.2	0
313	Artificial intelligence-based multi-class histopathologic classification of kidney neoplasms. <i>Journal of Pathology Informatics</i> , 2023, 14, 100299.	1.7	2
314	Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-na ^{ve} metastatic clear-cell renal cell carcinoma [™] A network meta-analysis. Focus on cabozantinib combined with nivolumab. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
315	SAMHD1-induced endosomal FAK signaling promotes human renal clear cell carcinoma metastasis by activating Rac1-mediated lamellipodia protrusion. <i>Experimental and Molecular Medicine</i> , 2023, 55, 779-793.	7.7	3
317	Estimated Direct Costs of Renal Cancer by Stage of Disease at Diagnosis and Phase of Its Management: A Whole-Disease Model. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e252-e260.	1.9	0
318	Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
319	Does the Immunohistochemical Expression of CD44, MMP-2, and MMP-9 in Association with the Histopathological Subtype of Renal Cell Carcinoma Affect the Survival of Patients with Renal Cancer?. <i>Cancers</i> , 2023, 15, 1202.	3.7	3
320	The association of healthy lifestyle index score and the risk of renal cell cancer in the Netherlands cohort study. <i>BMC Cancer</i> , 2023, 23, .	2.6	3

#	ARTICLE	IF	CITATIONS
321	AKI3-Risk Predictors and Scores in Radical Nephrectomy with High Thrombectomy under Extracorporeal Circulation for Renal Cell Carcinoma with Supradiaphragmatic Inferior Vena Cava/Right Atrial Thrombus: A Single-Centre Retrospective Study. <i>Medicina (Lithuania)</i> , 2023, 59, 386.	2.0	1
322	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma. <i>Current Oncology</i> , 2023, 30, 2457-2464.	2.2	1
323	Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4243.	4.1	4
324	Cause-specific mortality among patients with renal cell carcinoma in the United States from 2000 to 2018. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 209.e11-209.e20.	1.6	1
326	Transcriptome mapping of renal clear cell carcinoma revealed by machine learning algorithm based on enhanced computed tomography images. <i>Journal of Gene Medicine</i> , 2023, 25, .	2.8	0
327	Variation in the management of cT1 renal cancer by surgical hospital volume: A nationwide study. <i>BJUI Compass</i> , 2023, 4, 455-463.	1.3	2
328	Endoplasmic Reticulum Stress in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4914.	4.1	3
329	Imaging Recommendations for Diagnosis, Staging, and Management of Renal Tumors. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2023, 44, 084-092.	0.2	1
330	Bridging radiomics to tumor immune microenvironment assessment in clear cell renal cell carcinoma. , 2023, , .		1
331	Secondary Breast Malignancy from Renal Cell Carcinoma: Challenges in Diagnosis and Treatmentâ€”Case Report. <i>Diagnostics</i> , 2023, 13, 991.	2.6	1
332	Unique Characteristics of Patients with Von Hippelâ€”Lindau Disease Defined by Various Diagnostic Criteria. <i>Cancers</i> , 2023, 15, 1657.	3.7	1
333	Comprehensive analysis of the expression, prognostic value and biological importance of OVOâ€”like proteins in clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2023, 25, .	1.8	1
334	Role of the human solute carrier family 14 member 1 gene in hypoxia-induced renal cell carcinoma occurrence and its enlightenment to cancer nursing. <i>BMC Molecular and Cell Biology</i> , 2023, 24, .	2.0	0
335	Long non-coding RNAs enable precise diagnosis and prediction of early relapse after nephrectomy in patients with renal cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
336	<sc>KLF9</sc> inhibits the proliferation, invasion, and migration of renal cell carcinoma through the <sc>SDF</sc>â€”1</sc><sc>CXCR4</sc> axis. <i>Kaohsiung Journal of Medical Sciences</i> , 2023, 39, 587-595.	1.9	2
337	Ketorolac modulates Rac-1/HIF-1Î±/DDX3/Î²-catenin signalling via a tumor suppressor prostate apoptosis response-4 (Par-4) in renal cell carcinoma. <i>Scientific Reports</i> , 2023, 13, .	3.3	3
338	A novel oxidative-stress related lncRNA signature predicts the prognosis of clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
339	Imaging Techniques to Determine Degree of Sarcopenia and Systemic Inflammation in Advanced Renal Cell Carcinoma. <i>Current Urology Reports</i> , 2023, 24, 317-334.	2.2	3

#	ARTICLE	IF	CITATIONS
340	Gallstones, Cholecystectomy, and Kidney Cancer: Observational and Mendelian Randomization Results Based on Large Cohorts. <i>Gastroenterology</i> , 2023, 165, 218-227.e8.	1.3	8
341	MicroRNA-142-3p promotes renal cell carcinoma progression by targeting RhoBTB3 to regulate HIF-1 signaling and GGT/GSH pathways. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
342	Correlation between CXCR4 and MMP-2 Expression with T Stage in Clear Cell Renal Cell Carcinoma. <i>Research Journal of Pharmacy and Technology</i> , 2023, , 821-829.	0.8	1
343	⁶⁸ Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC. <i>Clinical Nuclear Medicine</i> , 2023, 48, e294-e296.	1.3	1
346	MicroRNA-155-5p Targets JADE-1, Promoting Proliferation, Migration, and Invasion in Clear Cell Renal Cell Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7825.	4.1	0
347	Cutaneous metastasis as the first presentation of poorly differentiated renal cell carcinoma: A case report. <i>Urology Case Reports</i> , 2023, 49, 102430.	0.3	0
348	Alcohol consumption and socioeconomic status associated with the risk of kidney cancer in a large Australian cohort study. <i>Annals of Epidemiology</i> , 2023, 84, 16-24.	1.9	1
349	Hydropneumothorax as a Presentation of Birt-Hogg-DubÃ© Syndrome. <i>Cureus</i> , 2023, , .	0.5	0
350	In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2023, 15, 2586.	3.7	2
351	Exploring the therapeutic and anti-tumor properties of morusin: a review of recent advances. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	2
352	Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century. <i>Cancers</i> , 2023, 15, 2782.	3.7	0
353	Racial disparities in nephrectomy and mortality among patients with renal cell carcinoma: Findings from SEER. <i>PLOS Global Public Health</i> , 2023, 3, e0001314.	1.6	0
354	Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients. <i>Heliyon</i> , 2023, 9, e15925.	3.2	0
355	Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas. <i>Current Issues in Molecular Biology</i> , 2023, 45, 4763-4777.	2.4	1
356	A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer models. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
357	Tumoricidal Activity of Simvastatin in Synergy with RhoA Inactivation in Antimigration of Clear Cell Renal Cell Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9738.	4.1	0
358	Percutaneous radiofrequency ablation is an effective treatment option for small renal masses, comparable to partial nephrectomy. <i>European Radiology</i> , 0, , .	4.5	1
359	Perioperative acute kidney injury in surgical treatment of renal cancer: pathogenesis, therapy of early and late complications. <i>IssledovaniÃ© I Praktika V Medicine</i> , 2023, 10, 104-117.	0.5	0

#	ARTICLE	IF	CITATIONS
360	<i>APOL1</i> genotype in African American patients with kidney neoplasm. Journal of Onco-Nephrology, 0, , 239936932311777.	0.6	0
361	Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma. Cancers, 2023, 15, 3159.	3.7	1
362	Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies. Cancers, 2023, 15, 3207.	3.7	5
363	Teaching Case: Radiation Myonecrosis Following Stereotactic Body Radiation Therapy in Metastatic Renal Cell Carcinoma. Applied Radiation Oncology, 0, , .	0.5	0
364	A Comparison of Microwave Ablation and Cryoablation for the Treatment of Renal Cell Carcinoma: A Systematic Literature Review and Meta-analysis. Urology, 2023, 180, 1-8.	1.0	1
365	Chasing the Role of miRNAs in RCC: From Free-Circulating to Extracellular-Vesicle-Derived Biomarkers. Biology, 2023, 12, 877.	2.8	1
366	Development and External Validation of Machine Learning-Based Models for Predicting Lung Metastasis in Kidney Cancer: A Large Population-Based Study. International Journal of Clinical Practice, 2023, 2023, 1-13.	1.7	0
367	Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which MSH3 is a key gene during disulfidptosis. Frontiers in Immunology, 0, 14, .	4.8	7
368	Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands. Frontiers in Oncology, 0, 13, .	2.8	0
369	Cancer associated macrophage-like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time. Scientific Reports, 2023, 13, .	3.3	0
370	Heart Metastases of Clear Cell Renal Cell Carcinoma. Diagnostics, 2023, 13, 1600.	2.6	0
371	Redox Signaling Modulates Activity of Immune Checkpoint Inhibitors in Cancer Patients. Biomedicines, 2023, 11, 1325.	3.2	1
372	Analysis of outcomes of the first line systemic therapy in patients with solitary, single and multiple metastases of renal cell carcinoma. Urologicheskie Vedomosti, 2023, 13, 15-21.	0.3	0
373	The Roles of Extracellular Vesicles in the Progression of Renal Cell Carcinoma and Their Potential for Future Clinical Application. Nanomaterials, 2023, 13, 1611.	4.1	1
374	The prognostic role of cigarette smoking in Kidney Cancer Survival. Cancer Medicine, 2023, 12, 14756-14766.	2.8	1
375	Cardiac safety profile of type II kinase inhibitors: Analysis of post-marketing reports from databases of European Medicine Agency & World Health Organization. DARU, Journal of Pharmaceutical Sciences, 0, , .	2.0	0
376	Posterior Reversible Encephalopathy Syndrome after Pazopanib Therapy. Diseases (Basel, Switzerland), 2023, 11, 76.	2.5	5
377	An International Survey of Genitourinary and Renal Pathologists Regarding Evaluation of the Non-Neoplastic Parenchyma in Kidney Cancer Specimens. International Journal of Surgical Pathology, 0, , 106689692311774.	0.8	0

#	ARTICLE	IF	CITATIONS
378	Comparing the outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a network meta-analysis. <i>BJU International</i> , 2023, 132, 353-364.	2.5	6
379	A Contemporary Clinicopathologic Analysis of Patients With Renal Cell Carcinoma and Vena Cava Involvement. <i>International Journal of Surgical Pathology</i> , 0, , .	0.8	0
380	Standardized Follow-Up Recommendations Improve Reporting of Incidental Renal Lesions in a Community Setting. <i>Cureus</i> , 2023, , .	0.5	0
381	Radiomics and Ki-67 index predict survival in clear cell renal cell carcinoma. <i>British Journal of Radiology</i> , 2023, 96, .	2.2	1
383	The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
384	Ultrasound Elastography for the Differentiation of Benign and Malignant Solid Renal Masses: A Systematic Review and Meta-Analysis. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 7767.	2.5	0
385	MiR-1236: Key controller of tumor development and progression: Focus on the biological functions and molecular mechanisms. <i>Pathology Research and Practice</i> , 2023, 248, 154671.	2.3	0
386	Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
387	Utility of multiparametric renal CT for differentiation of low-grade from high-grade cT1a clear cell renal cell carcinoma. <i>British Journal of Radiology</i> , 2023, 96, .	2.2	0
389	Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma. <i>Oncologist</i> , 2023, 28, 1079-1084.	3.7	0
390	Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
391	A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 853-863.	2.4	0
392	Microfluidic-based prostate cancer model for investigating the secretion of prostate-specific antigen and microRNAs in vitro. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
393	Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers. <i>Diagnostics</i> , 2023, 13, 2430.	2.6	2
394	CD105 in the progression and therapy of renal cell carcinoma. <i>Cancer Letters</i> , 2023, 570, 216327.	7.2	1
396	Protein disulfide isomerase family mediated redox regulation in cancer. <i>Advances in Cancer Research</i> , 2023, , .	5.0	1
397	SLUG and SNAIL as Potential Immunohistochemical Biomarkers for Renal Cancer Staging and Survival. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12245.	4.1	1
398	Interobserver reproducibility of RENAL nephrometry score in comparison to simplified PADUA Renal nephrometry score. <i>Urology Annals</i> , 2023, 15, 373-382.	0.6	0

#	ARTICLE	IF	CITATIONS
399	Serum Oxidative and Nitrosative Stress Markers in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2023, 15, 3995.	3.7	1
400	Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old. <i>International Journal of Clinical Oncology</i> , 2023, 28, 1530-1537.	2.2	0
401	Expert Consensus on the management of Advanced clear-cell Renal cell carcinoma: Indian Perspective (PEARL-INDIA). <i>BMC Cancer</i> , 2023, 23, .	2.6	0
403	Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 51, 295-303.	6.4	2
404	Renal cell carcinoma in a patient with staghorn stones: A case report. <i>International Journal of Surgery Case Reports</i> , 2023, 110, 108678.	0.6	0
405	Pesticides and Cancer. , 2023, , 177-211.		0
406	Identification of natural inhibitor from <i>Aframomum melegueta</i> targeting survivin and mammalian rapamycin signaling pathway in Kidney Cancer. <i>Informatics in Medicine Unlocked</i> , 2023, 41, 101320.	3.4	0
407	A Neurosurgical Perspective on Brain Metastases from Renal Cell Carcinoma: Multi-Institutional, Retrospective Analysis. <i>Biomedicines</i> , 2023, 11, 2485.	3.2	1
408	Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2023, , .	1.9	0
409	Inhibition of cMYC-MAX transcription factors hetero-dimerization with structurally engineered oMOYC to downregulate oncogenic pathways in renal carcinoma. <i>Computers in Biology and Medicine</i> , 2023, 164, 107257.	7.0	0
410	A Comparison of Histotripsy and Percutaneous Cryoablation in a Chronic Healthy Swine Kidney Model. <i>Journal of Vascular and Interventional Radiology</i> , 2023, 34, 1986-1996.	0.5	0
411	The potential association between influenza vaccination and lower incidence of renal cell carcinoma. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.9	0
412	Morbidity of elective surgery for localized renal masses among elderly patients: A contemporary multicenter study. <i>European Journal of Surgical Oncology</i> , 2023, 49, 107014.	1.0	0
413	Nonalcoholic Fatty Liver Disease and Extrahepatic Malignancies. , 2023, , 195-202.		0
414	Protein kinase inhibitors in the management of clear cell renal cell carcinoma metastatic to the iris. <i>Journal Francais D'Ophtalmologie</i> , 2023, , .	0.4	0
415	Kidney Function and Risk of Renal Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , OF1-OF7.	2.5	0
416	Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
417	Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma. <i>Oncotarget</i> , 2023, 14, 807-808.	1.8	0

#	ARTICLE	IF	CITATIONS
418	Late Recurrence of Renal Cell Carcinoma in Unusual Sites 23 Years After Nephrectomy. <i>Cureus</i> , 2023, , .	0.5	0
419	Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies. <i>Kidney Cancer</i> , 2023, 7, 123-136.	0.4	0
420	Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I/II clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	0
421	Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 43 cases with a focus on the expression of KRAS signaling pathway downstream effectors. <i>Human Pathology</i> , 2023, 142, 1-6.	2.0	2
422	Smoking enhanced the expression of c-kit in chromophobe renal cell carcinoma. <i>Tobacco Induced Diseases</i> , 2023, 21, 1-9.	0.6	0
423	Perioperative systemic therapy in renal cell carcinoma. <i>Current Opinion in Supportive and Palliative Care</i> , 2023, 17, 301-307.	1.3	0
424	Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9). <i>Clinical Genitourinary Cancer</i> , 2024, 22, 126-133.e2.	1.9	0
425	Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 115-125.e3.	1.9	0
426	Knockdown of NR3C1 inhibits the proliferation and migration of clear cell renal cell carcinoma through activating endoplasmic reticulum stressâ€“mitophagy. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	1
427	Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience. <i>Medicine (United States)</i> , 2023, 102, e35245.	1.0	0
428	The Metastasis Pattern of Renal Cell Carcinoma Is Influenced by Histologic Subtype, Grade, and Sarcomatoid Differentiation. <i>Medicina (Lithuania)</i> , 2023, 59, 1845.	2.0	0
429	High Expression of Mannosyl-Oligosaccharide Glucosidase Is Associated with Poor Prognosis of Renal Clear Cell Carcinoma. <i>IFMBE Proceedings</i> , 2024, , 891-900.	0.3	0
430	Polarization-sensitive optical coherence tomography for renal tumor detection in ex vivo human kidneys. <i>Optics and Lasers in Engineering</i> , 2024, 173, 107900.	3.8	0
431	Identification of anoikis-related subtypes and immune landscape in kidney renal clear cell carcinoma. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
432	Retroperitoneoscopic Clampless, Sutureless Hybrid Therapy in the Management of Renal Hilar Tumors. <i>Annals of Surgical Oncology</i> , 2024, 31, 681-687.	1.5	1
433	The immunoreactivity of GLI1 and VEGFA is a potential prognostic factor in kidney renal clear cell carcinoma. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
434	PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches. <i>Biomedicines</i> , 2023, 11, 3095.	3.2	0
435	Mathematical and Machine Learning Models of Renal Cell Carcinoma: A Review. <i>Bioengineering</i> , 2023, 10, 1320.	3.5	0

#	ARTICLE	IF	CITATIONS
436	Computational analysis of protein-protein interactions of cancer drivers in renal cell carcinoma. <i>FEBS Open Bio</i> , 0, , .	2.3	0
437	Silver Nanoparticles (AgNPs) as Enhancers of Everolimus and Radiotherapy Sensitivity on Clear Cell Renal Cell Carcinoma. <i>Antioxidants</i> , 2023, 12, 2051.	5.1	0
438	Gut microbiota and immunotherapy of renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
439	Management of Renal Cell Carcinoma with IVC Thrombus, Nodal Involvement, and T4 Disease. , 2023, , 143-181.		0
440	Downstaging and Pathological Complete Response of Locally Recurrent Sarcomatoid Renal Cell Carcinoma under Pembrolizumab and Lenvatinib: A Case Report and Review of Literature. <i>Case Reports in Oncology</i> , 2023, 16, 1245-1252.	0.7	1
441	Clinically Silent, Metastatic Renal Cell Carcinoma Detected on Routine Screening Mammogram: A Report of a Rare Case and Review of Literature. <i>Cureus</i> , 2023, , .	0.5	0
442	Partial versus radical nephrectomy for T1b renal cell carcinoma: A comparison of efficacy and prognostic factors based on the Surveillance, Epidemiology, and End Results database. <i>Current Urology</i> , 0, , .	0.6	0
443	The association of C-reactive protein with major depressive symptoms in nonmetastatic renal cell carcinoma. <i>Journal of Psychosocial Oncology Research and Practice</i> , 2023, 5, .	0.5	0
444	Emergency Physician-Performed Point-of-Care Ultrasound of a Renal Mass. <i>Cureus</i> , 2023, , .	0.5	0
445	Nuclear Receptor PPAR α as a Therapeutic Target in Diseases Associated with Lipid Metabolism Disorders. <i>Nutrients</i> , 2023, 15, 4772.	4.1	1
446	A case report of liver infiltration from a large renal cell carcinoma: Diagnostic and management enigma. <i>International Journal of Surgery Case Reports</i> , 2024, 114, 109045.	0.6	0
447	Kidney cancer: Links between hereditary syndromes and sporadic tumorigenesis. <i>Seminars in Diagnostic Pathology</i> , 2023, , .	1.5	0
448	Distinct spatial landscapes in clear cell renal cell carcinoma as revealed by whole transcriptome analysis. <i>Immuno-Oncology Technology</i> , 2023, , 100690.	0.3	0
449	Tumor-to-tumor spread: a case report and literature review of renal cell carcinoma metastasis into thyroid cancer. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	0
450	circWSB1 promotes tumor progression in ccRCC via circWSB1/miR-182-5p/WSB1 axis. <i>International Journal of Biological Macromolecules</i> , 2024, 256, 128338.	7.5	0
451	Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 295-304.e6.	1.9	0
452	Role of clinicopathological variables in predicting recurrence and survival outcomes after surgery for non-metastatic renal cell carcinoma: Systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2024, 154, 1309-1323.	5.1	1
453	Prognostic significance of annexin A2 and tumor associated macrophages (TAMs) in metastatic renal cell carcinoma and their relation to Sunitinib resistance. <i>Journal of Immunoassay and Immunochemistry</i> , 2024, 45, 1-19.	1.1	0

#	ARTICLE	IF	CITATIONS
454	Inflammation and Immunity Gene Expression Patterns and Machine Learning Approaches in Association with Response to Immune-Checkpoint Inhibitors-Based Treatments in Clear-Cell Renal Carcinoma. <i>Cancers</i> , 2023, 15, 5637.	3.7	0
455	A Case of Metastatic Renal Cell Carcinoma to the Maxillary Sinus Initially Presenting as Recurrent Epistaxis. , 2023, 1, .		2
456	Attention 3D-CU-Net: Enhancing Kidney Tumor Segmentation Accuracy Through Selective Feature Emphasis. <i>IEEE Access</i> , 2023, 11, 139798-139810.	4.2	0
457	Association between time from diagnosis to initiation of systemic therapy of metastatic renal cell carcinoma with treatment outcome. <i>Medicinski Podmladak</i> , 2023, 74, 64-68.	0.0	0
458	Exosomes from Von Hippel-Lindau-Null Cancer Cells Promote Metastasis in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 17307.	4.1	0
459	Is chest imaging needed as part of pT1a renal cell carcinoma surveillance after surgical resection?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2024, 42, 23.e1-23.e4.	1.6	0
460	High-Intensity Focused Ultrasound Surgery for Tumor Ablation: A Review of Current Applications. <i>Radiology Imaging Cancer</i> , 2024, 6, .	1.6	1
461	LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. <i>Future Oncology</i> , 2023, 19, 2631-2640.	2.4	0
462	Collateral vessels on preoperative enhanced computed tomography for predicting pathological grade of clear cell renal cell carcinoma: A retrospective study. <i>European Journal of Radiology</i> , 2024, 170, 111240.	2.6	0
463	The results of surgery for renal cell carcinoma metastases of the pancreas. <i>Scandinavian Journal of Gastroenterology</i> , 2024, 59, 354-360.	1.5	0
464	Simultaneous surgical management of renal cancer with atrial thrombotic extension and severe chronic coronary artery disease: a case report. <i>Journal of Medical Case Reports</i> , 2023, 17, .	0.8	0
465	Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies. <i>BJUI Compass</i> , 0, , .	1.3	0
466	Renal functional outcomes after robot-assisted partial nephrectomy and percutaneous cryoablation of clinical T1 renal cell carcinoma – A prospective study. <i>Journal of Clinical Imaging Science</i> , 0, 13, 37.	1.1	1
467	Convolutional Neural Network Model for Segmentation and Classification of Clear Cell Renal Cell Carcinoma Based on Multiphase CT Images. <i>Journal of Imaging</i> , 2023, 9, 280.	3.0	1
468	Mesenchymalâ€“Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 17582.	4.1	0
469	Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 394-401.	1.9	0
470	Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. <i>Cells</i> , 2024, 13, 34.	4.1	1
471	Cuproptosis geneâ€“related, neural networkâ€“based prognosis prediction and drugâ€“target prediction for <sc>KIRC</sc>. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0

#	ARTICLE	IF	CITATIONS
472	Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC. <i>International Journal of Molecular Sciences</i> , 2024, 25, 216.	4.1	0
473	Percutaneous cryoablation of 100 anterior renal tumors: safety and technical success. <i>Abdominal Radiology</i> , 2024, 49, 919-926.	2.1	0
474	Withanolides: Promising candidates for cancer therapy. <i>Phytotherapy Research</i> , 2024, 38, 1104-1158.	5.8	0
476	Mining and validation of prognosis of various visceral metastasis in renal cell carcinoma: a study based on SEER database. <i>Updates in Surgery</i> , 2024, 76, 657-676.	2.0	0
477	Therapeutic Options in Metastatic Renal Cancer. <i>Hellenic Urology</i> , 2022, 34, 128-135.	0.1	0
478	Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2024, 13, 307.	2.4	0
479	A serum panel of three microRNAs may serve as possible biomarkers for kidney renal clear cell carcinoma. <i>Cancer Cell International</i> , 2024, 24, .	4.1	0
480	Differences in cancer presentation, treatment, and mortality between rural and urban patients diagnosed with kidney cancer in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2024, 42, 72.e9-72.e17.	1.6	0
481	Polygenic risk score model for renal cell carcinoma in the Korean population and relationship with lifestyle-associated factors. <i>BMC Genomics</i> , 2024, 25, .	2.8	0
482	Simplified cardiovascular index may be the best comorbidity index for clinical use in prediction of mortality for renal cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2024, 42, 72.e1-72.e8.	1.6	0
483	Exploring the anticancer potential of hydrogen sulfide and BAYâ€™876 on clear cell renal cell carcinoma cells: Uncovering novel mutations in VHL and KDR genes among ccRCC patients. <i>Molecular and Clinical Oncology</i> , 2024, 20, .	1.0	0
484	The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy. <i>International Journal of Molecular Sciences</i> , 2024, 25, 1499.	4.1	0
485	Ring Finger Protein 34 (RNF34) as a Prognostic Biomarker for Clear Cell Renal Cell Carcinoma. <i>Cureus</i> , 2024, , .	0.5	0
486	Renal Cell Carcinoma Metastasis to the Small Bowel: A Rare Finding 10 Years After Nephrectomy. <i>Cureus</i> , 2024, , .	0.5	0
487	Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival. <i>Cancers</i> , 2024, 16, 557.	3.7	1
488	Comparison of outcomes for Hispanic and nonâ€™Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database. <i>Cancer</i> , 0, , .	4.1	0
489	The Impact of a Multidisciplinary Tumor Board (MTB) on Treatment Decision Making for Patients With Renal Cell Carcinoma (RCC): 5-Year Data Analysis. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 610-617.e1.	1.9	0
491	Molecularly Defined Renal Carcinomas. <i>Kidney Cancer</i> , 2024, 8, 31-44.	0.4	0

#	ARTICLE	IF	CITATIONS
492	EMX2 inhibits clear cell renal cell carcinoma progress via modulating Akt/FOXO3a pathway. <i>Molecular Carcinogenesis</i> , 2024, 63, 951-961.	2.7	0
493	Deep learning algorithm (YOLOv7) for automated renal mass detection on contrast-enhanced MRI: a 2D and 2.5D evaluation of results. <i>Abdominal Radiology</i> , 2024, 49, 1194-1201.	2.1	0
494	Prognostic value of preoperative radiographic perinephric fat features in renal cell carcinoma patients undergoing surgery. <i>Asian Journal of Surgery</i> , 2024, 47, 2188-2194.	0.4	0
495	Percutaneous Ablative Techniques for Liver and Kidney Cancer. , 2023, , 441-446.		0
496	Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study. <i>Onkourologiya</i> , 2024, 19, 32-43.	0.3	0
497	Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas. <i>Research Journal of Pharmacy and Technology</i> , 2024, , 109-114.	0.8	0
498	The lncRNA Signature Associated with Basement Membrane as a Novel Biomarker of Prognostic Significance and Identification for Clear Cell Renal Cell Carcinoma. <i>Advances in Clinical Medicine</i> , 2024, 14, 4730-4742.	0.0	0
499	Development of a Nomogram Model to Identify Appropriate Candidates from Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Based on the Surveillance, Epidemiology and End Results Database. <i>Clinical Genitourinary Cancer</i> , 2024, , 102062.	1.9	0
500	Single-cell transcriptomic analysis in clear cell renal cell carcinoma: Deciphering the role of <sc>APP</sc> within the tumour microenvironment. <i>Journal of Cellular and Molecular Medicine</i> , 2024, 28, .	3.6	0
501	Prevalence of Renal Neoplasia in Autosomal Dominant Polycystic Kidney Disease: Systematic Review and Meta-Analysis. <i>Nephron</i> , 0, , 1-11.	1.8	0
503	Integrative Analysis of Germline Rare Variants in Clear and Non-clear Cell Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2024, 62, 107-122.	0.4	0
504	Sarcoid-like reaction and hypothyroidism induced by PD-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review. <i>BMC Pulmonary Medicine</i> , 2024, 24, .	2.0	0
505	The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line. <i>European Journal of Clinical Pharmacology</i> , 0, , .	1.9	0
506	Renal cell carcinoma metastasizing to salivary glands: Systematic review. <i>National Journal of Maxillofacial Surgery</i> , 2024, 15, 3-17.	0.5	0
507	Exosomes in renal cell carcinoma: challenges and opportunities. <i>Molecular Biology Reports</i> , 2024, 51, .	2.3	0